The Oncology Institute, Inc. (NASDAQ:TOI) Short Interest Update

The Oncology Institute, Inc. (NASDAQ:TOI) was the target of a large increase in short interest in December. As of December 31st, there was short interest totalling 324,100 shares, an increase of 86.8% from the December 15th total of 173,500 shares. Currently, 0.9% of the company’s stock are short sold. Based on an average trading volume of 1,740,000 shares, the days-to-cover ratio is presently 0.2 days.

Oncology Institute Stock Performance

Shares of Oncology Institute stock traded up $0.08 during trading on Thursday, reaching $0.48. The company’s stock had a trading volume of 1,225,425 shares, compared to its average volume of 760,344. The firm has a market cap of $36.04 million, a PE ratio of -0.61 and a beta of 0.13. The company has a 50-day moving average price of $0.24 and a two-hundred day moving average price of $0.33. The company has a current ratio of 2.49, a quick ratio of 2.27 and a debt-to-equity ratio of 5.91. Oncology Institute has a fifty-two week low of $0.13 and a fifty-two week high of $2.45.

Insider Transactions at Oncology Institute

In related news, Director Brad Hively acquired 250,000 shares of Oncology Institute stock in a transaction dated Tuesday, November 26th. The stock was acquired at an average price of $0.17 per share, for a total transaction of $42,500.00. Following the transaction, the director now owns 616,753 shares of the company’s stock, valued at $104,848.01. This represents a 68.17 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 9.50% of the company’s stock.

Hedge Funds Weigh In On Oncology Institute

A hedge fund recently raised its stake in Oncology Institute stock. HighTower Advisors LLC grew its position in The Oncology Institute, Inc. (NASDAQ:TOI) by 190.8% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 81,362 shares of the company’s stock after acquiring an additional 53,382 shares during the period. HighTower Advisors LLC owned about 0.11% of Oncology Institute worth $27,000 at the end of the most recent quarter. 36.86% of the stock is currently owned by institutional investors and hedge funds.

About Oncology Institute

The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services.